Company intelligence / Profile preview

Hexal AG

Holzkirchen, Bavaria, Germanyhexal.de ↗

Ownership: Private
Employees: ~7000
Development stage: Commercial

Overview

Hexal is a leading German pharmaceutical company specializing in generic drugs and biosimilars, with several products approved for use in the EU and other regions. Its portfolio includes both small molecule generics and complex biologic medicines, including biosimilars for serious diseases such as cancer and immune disorders. The company has a strong R&D focus on differentiated dosage forms and delivery systems, as well as ongoing development of new biosimilar products.[1][5][8]

Therapeutic areas: NephrologyOncologyHematologyDermatologyNeurology
Modalities: Small moleculesBiosimilars (biologics)[5][8]
Industry: Pharma

Partnerships

Part of the global Sandoz networkcollaborations within Novartis/Sandoz ecosystemmember of Flying Health innovation ecosystem.[10]

Beyond the preview

Go deeper on Hexal AG.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hexal AG.

Explore the full profile